Screening epidemiological program on compensation evaluation of Diabetes Mellitus type 2 (DMT2) patients on oral anti-diabetic (OAD) monotherapy and physicians satisfaction of their usage
Study identifier:NIS-CRU-ONG-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Screening epidemiological program on compensation evaluation of DM type 2 patients on OAD monotherapy and physicians satisfaction of their usage
Medical condition
Type 2 Diabetes
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
1849
Study type
Observational
Age
35 Years +
Date
Study Start Date: 01 Dec 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Bristol Meyers Squibb
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program | - |
Contacts
Investigators
Principal Investigator
Alexey Stepanov
AstraZeneca
